Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer: A Dose-Escalation Study
- 30 November 2009
- journal article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 2 (11) , 1095-1101
- https://doi.org/10.1016/j.jcin.2009.08.018
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The drug-drug interaction between proton pump inhibitors and clopidogrelCMAJ : Canadian Medical Association Journal, 2009
- Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent ThrombosisThe American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEuropean Heart Journal, 2008
- CYP2C19 and Nongenetic Factors Predict Poor Responsiveness to Clopidogrel Loading dose after Coronary Stent ImplantationPharmacogenomics, 2008
- Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and ClopidogrelThe Journal of Clinical Pharmacology, 2008
- Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12 , and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery DiseaseStroke, 2005
- The Value of Clopidogrel in Addition to Standard Therapy in Reducing Atherothrombotic EventsPharmacoEconomics, 2004